Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698951 | 0.74 | SMARCA2 (0.46) | KMT2AALDH1A1MEN1RIPK1NR2F2 | |
| SCHEMBL4270598 | 0.71 | ALDH1A1 (0.37) | KMT2AALDH1A1POLBMEN1NR2F2 | |
| SCHEMBL3766141 | 0.70 | BCAT2 (0.40) | KMT2AALDH1A1POLBMEN1SMN1; SMN2 | |
| SCHEMBL3765678 | 0.70 | ALDH1A1 (0.44) | KMT2AALDH1A1POLBSMN1; SMN2CYP1A2 | |
| SCHEMBL38661651 | 0.70 | ALDH1A1 (0.33) | KMT2AALDH1A1POLB | |
| SCHEMBL3765780 | 0.70 | BCHE (0.41) | KMT2AALDH1A1POLBMEN1SMN1; SMN2 | |
| SCHEMBL38664216 | 0.69 | NLRP3 (0.39) | ALDH1A1POLBCYP1A2CYP2C19 | |
| SCHEMBL3765674 | 0.68 | LMNA (0.43) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL9984900 | 0.67 | BCHE (0.56) | KMT2AALDH1A1POLBMEN1SMN1; SMN2 | |
| SCHEMBL3760987 | 0.67 | POLB (0.56) | KMT2AALDH1A1POLBMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | FFAR2 258/4885KMT2A 261/4885ALDH1A1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.